Zyprexa
(olanzapine)ApprovedSmall molecule
Olanzapine is used to treat schizophrenia and bipolar disorder by helping to balance certain chemicals in the brain that affect mood and thinking. It can help reduce hallucinations, delusions, and mood swings.[2] Zyprexa is currently approved and in use across 51 indications[4].[1]
Zyprexa is one of 905 small molecule programs targeting Insulin resistance. It is currently in Approved.
51
Indications
313
Total Trials
17
Active Trials
904
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 47 indications
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Zyprexa
MMODAG GmbH
Approved
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Systematic Therapy
PPeking University Third Hospital
Preclinical
CEA-Targeted CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia51 trials
Show 48 more trials
Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia
Completed·—·Phase 4·NCT03304457·100 enrolled
Metabolic Profile and Anthropometric Changes in Schizophrenia
Completed·—·N/A·NCT00534183·2,006 enrolled
Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients
Completed·—·Phase 4·NCT01149577·25 enrolled
Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00239109·112 enrolled
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
Completed·—·Phase 4·NCT01164059·149 enrolled
Polypharmacy in Clozapine-resistant Schizophrenia
Completed·—·Phase 4·NCT00918021·30 enrolled
A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia
Completed·—·N/A·NCT02192723·550 enrolled
Trial and Follow-up of the Efficacy of Two-stage Integrated Treatment for Chinese Schizophrenia Inpatients
Unknown status·—·N/A·NCT02850445·170 enrolled
Olanzapine19 trials
Show 16 more trials
Ziprasidone And Olanzapine's Outcomes In Mania
Terminated·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00329108·29 enrolled
Nausea and vomiting10 trials
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting
Recruiting·—·Phase 3·NCT07208305·222 enrolled
"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
Completed·—·Phase 3·NCT03219710·240 enrolled
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02290470·81 enrolled
Show 7 more trials
Bipolar I Disorder7 trials
Show 4 more trials
Schizoaffective Disorder6 trials
Show 3 more trials
65 more indications
Treatment6 trials
Agitation5 trials
Efficacy and Safety5 trials
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
Terminated·—·Phase 2·NCT02088060·150 enrolled
Bipolar Disorder5 trials
Chemotherapy-induced nausea and vomiting4 trials
Show 1 more trial
Antipsychotics4 trials
Antipsychotics and Risk of Hyperglycemic Emergencies
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02582736·725,489 enrolled
Treatment Resistant Depression3 trials
Anorexia Nervosa3 trials
Chemotherapy3 trials
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
Completed·—·Phase 3·NCT02635984·108 enrolled
Delirium3 trials
Borderline personality disorder3 trials
Vomiting3 trials
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
Recruiting·—·Phase 3·NCT06588413·172 enrolled
Weight Gain2 trials
Metabolism2 trials
Tic Disorder2 trials
Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder
Unknown status·—·Phase 4·NCT03857581·100 enrolled
Insulin Sensitivity2 trials
Depression2 trials
Interaction2 trials
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Completed·—·Phase 1·NCT02051387·74 enrolled
Cardiovascular1 trial
Autism1 trial
Long-Term Olanzapine Treatment in Children With Autism
Completed·—·Phase 2/3·NCT00183404·32 enrolled
Cognitive Change1 trial
TIPS1 trial
Medication1 trial
Immunotherapy1 trial
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Not yet recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 2·NCT06554613·156 enrolled
Major Depression1 trial
Optimal Duration of Olanzapine Add-on Therapy in Major Depression
Withdrawn·—·Phase 3·NCT00568672
Cancer-related Pain1 trial
AIN1 trial
Huntington disease1 trial
Monotherapy1 trial
Adolescent1 trial
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
Recruiting·FFirst Affiliated Hospital of Chongqing Medical University·Phase 1/2·NCT05814640·520 enrolled
Effectiveness1 trial
Pathological Gambling1 trial
Cancer Pain1 trial
Antidepressants1 trial
Quality of Recovery1 trial
Amyotrophic Lateral Sclerosis1 trial
Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)
Completed·—·Phase 2/3·NCT00876772·40 enrolled
Anorexia1 trial
Major Depressive Disorder1 trial
Cognitive impairment1 trial
Weight loss1 trial
Maintenance Treatment1 trial
Observational Study1 trial
Safety and Efficacy1 trial
Megestrol Acetate1 trial
Lung Cancer1 trial
Psychiatric Disorder1 trial
Diabetes in Neuropsychiatric Disorders
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1/2·NCT00446992·30 enrolled
Dexamethasone1 trial
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Recruiting·—·Phase 3·NCT07413809·92 enrolled
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Sep 30, 1996
ZYPREXA
NDA NDA020592
Apr 6, 2000
ZYPREXA ZYDIS
NDA NDA021086
Mar 29, 2004
ZYPREXA
NDA NDA021253
Dec 11, 2009
ZYPREXA RELPREVV
NDA NDA022173
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Zyprexa drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for olanzapine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- D2-Like Dopamine Receptor Antagonist; Serotonin 2c (5-Ht2c) Receptor Antagonist; Serotonin 2a (5-Ht2a) Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- MMODAG GmbH